Skip to main content
Now MHRA approved in the UK (10 August 2026). Foundayo is prescription only. We do not sell medicines, issue prescriptions or give personal medical advice.

Stopping Foundayo and keeping the weight off: the honest guide

Nobody selling weight loss medicine leads with what happens when you stop, so we will: without a plan, much of the weight tends to come back. That's not a moral failing, it's biology, and knowing it upfront is how you beat it.

Last verified: 12 August 2026

The uncomfortable truth about stopping

Across GLP-1 medicines, the pattern in follow-up studies is consistent: when treatment stops, appetite returns to its old settings, and a substantial portion of lost weight is typically regained over the following year without deliberate countermeasures. Foundayo doesn't cure the biology of appetite; it manages it, the way blood pressure tablets manage blood pressure. That's not a reason to despair, it's the design brief for stopping well.

Why the weight comes back

When you lose weight, your body pushes back: hunger hormones rise, fullness signals weaken, and cravings sharpen, a response that persists long after the scales stop moving. The medicine quiets that push-back; remove it, and the push-back is still there waiting. People who understand this stop blaming willpower and start planning around biology, which is a far stronger position.

What actually helps it stick

  • Don't stop on a whim, and don't stop suddenly without a conversation. Talk to your prescriber first: they can discuss timing, whether stepping down the dose ladder gradually suits you, and what monitoring makes sense afterwards. Stopping because of cost or side effects both have alternatives worth hearing before you quit outright.
  • Bank the habits while the medicine makes them easy. The treatment window is training camp: protein-first meals, regular walking, resistance exercise twice a week, real cooking patterns. Habits built during treatment are the single biggest predictor of what survives after it.
  • Protect muscle on the way down. Muscle lost during rapid weight loss lowers the energy you burn at rest, making regain easier. Protein and strength work during treatment are your pension contributions for afterwards; our nutrition guide covers how.
  • Weigh in weekly after stopping and set a tripwire. Decide in advance the number at which you act, act meaning revisiting habits or contacting your prescriber, not spiralling. Catching a 3 kg drift is easy; discovering a 12 kg one is demoralising.
  • Keep the support structures. Free NHS programmes, community groups and honest tracking all outlast any prescription.

The middle path: maintenance rather than full stop

Stopping isn't binary. Some people, with their prescriber, hold a lower maintenance dose rather than climbing to the top and staying there. And notably, the ATTAIN-MAINTAIN trial showed people switching from injectable GLP-1s to daily orforglipron largely kept their weight off, evidence that a tablet can serve as the long-term maintenance layer after heavier treatment. If cost is what's pushing you to stop, maintenance dosing and provider switching are both worth pricing before quitting entirely; our price lists will carry dose-by-dose costs the moment UK pricing lands.

If you've already stopped and the weight is returning

First, no shame: it's the most common outcome and says nothing about your character. Second, act early rather than waiting for it all to return: re-anchor the habits that worked, and talk to a prescriber about options, which can include restarting treatment. Restarting typically means rejoining the dose ladder rather than leaping back to your old dose, so it's a planned conversation, not a panic purchase, and only ever from a GPhC registered provider.

Talk before you stop

However you leave Foundayo, do it with your prescriber in the loop: they can advise on tapering, timing around your circumstances, and what to watch for afterwards. If side effects are driving the decision, say so plainly, because dose adjustments solve more problems than quitting does.

Nick Johnson Founder and healthcare pricing analyst, Medstack Ltd

Nick founded Monj, iGovy, Ogovy and Frayo to bring honest, checkout-price comparison and provider verification to the UK weight management medicine market. His background is in IT and data, not pharmacy, which is exactly why the sites stay independent: no provider can buy a ranking, and awkward findings get published. Read more about Frayo and the team.